as someone already pointed out potential market is far greater...

as someone already pointed out potential market is far greater than present market of $240M as present test is ineffective.

Problem is there are several other companies at a similar stage of development as this one ie Yale university that looks to be even more effective.

Still market cap is very low but there is no money to speak of in the bank so a CAP raising is likely which makes some nervous of investing in it.
I guess if it was such a good buy Pfizer or MerK would have done a T/O
management seem ok though unlike many similar sized Bio techs.
I hold it